Cambridge biotech Agios Pharmaceuticals files for an IPO

Agios Pharmaceuticals Inc. is the latest Massachusetts biotechnology company to explore an initial public stock offering this year. In a regulatory documents, Cambridge-based Agios said it is planning to move forward with an IPO. According to an estimate by the Reuters news service, the company could raise up to $86 million in an initial public offering of common stock. Agios looks to use its expertise in cellular metabolism to develop treatments for cancer. In 2012, Agios reported revenue of ab...